Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation

BACKGROUND: Thrombocytopenia post hematopoietic stem-cell transplantation (HCT) usually contributes to poor outcomes with no standardized treatment. Eltrombopag and romiplostim can be feasible for post-HCT thrombocytopenia, but the use of avatrombopag has not yet been evaluated. OBJECTIVES: We aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Meng, Qi, Jiaqian, Gu, Chengyuan, Wang, Hong, Zhang, Ziyan, Wu, Depei, Han, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523859/
https://www.ncbi.nlm.nih.gov/pubmed/36185780
http://dx.doi.org/10.1177/20406207221127532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523859/
https://www.ncbi.nlm.nih.gov/pubmed/36185780
http://dx.doi.org/10.1177/20406207221127532

Ejemplares similares